N-(3-methoxyphenylmethyl)carbamic acid ethyl ester | 959922-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(3-methoxyphenylmethyl)carbamic acid ethyl ester
• 英文别名: (3-methoxy-benzyl)-carbamic acid ethyl ester；(3-Methoxy-benzyl)-carbamidsaeure-aethylester；3-methoxy-N-ethoxycarbonylbenzylamine；ethyl N-[(3-methoxyphenyl)methyl]carbamate
• CAS: 959922-04-4
• 化学式: C₁₁H₁₅NO₃
• mdl: MFCD20538828
• 分子量: 209.245
• InChiKey: IATPKDUDGLWVEK-UHFFFAOYSA-N

物化性质

• 沸点：
  346.9±25.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-methoxyphenylmethyl)carbamic acid ethyl ester 、 ethyl 4-methylbenzylcarbamate 生成 N-甲基-3-甲氧基苄胺 、 N-甲基-4-甲基苄胺
  参考文献：
  名称：

  3(2H)pyridazinone, process for its preparation and anti-allergic agent

  摘要：

  一种具有以下结构式的3(2H)吡啶并嗪酮化合物：其中R.sub.1是C.sub.2 -C.sub.5烷基；R.sub.2是氢、C.sub.1 -C.sub.3烷基、氯或溴；R.sub.3是氢或C.sub.1 -C.sub.4烷基；以及Y.sub.1、Y.sub.2和Y.sub.3中的每一个（可以相同也可以不同）是氢、C.sub.1 -C.sub.8烷基、C.sub.2 -C.sub.8烯基、卤素、--(CH.sub.2).sub.l A（其中A是具有以下结构式的取代氨基：--N(R.sub.4)(R.sub.5)（其中R.sub.4和R.sub.5可以相同也可以不同，为C.sub.1 -C.sub.4烷基，或R.sub.4和R.sub.5一起形成C.sub.4 -C.sub.6烷基）、吗啉基、4-R.sub.6-哌嗪-1-基（其中R.sub.6为C.sub.1 -C.sub.3烷基）或--OR.sub.7（其中R.sub.7为氢或C.sub.1 -C.sub.3烷基），l为0到3的整数，--OR.sub.8（其中R.sub.8为氢、C.sub.1 -C.sub.8烷基、C.sub.3 -C.sub.5烯基、苄基或--(CH.sub.2).sub.q --R.sub.9（其中R.sub.9为CO.sub.2R.sub.3（其中R.sub.3如上定义）、--CONHR.sub.3（其中R.sub.3如上定义）或--CH.sub.2OR.sub.7（其中R.sub.7如上定义），q为1到5的整数）]，--CO.sub.2R.sub.3（其中R.sub.3如上定义），--CON(R.sub.10)(R.sub.11)（其中R.sub.10和R.sub.11可以相同也可以不同，为氢、C.sub.1 -C.sub.4烷基或C.sub.3 -C.sub.5烯基，或R.sub.10和R.sub.11一起形成C.sub.4 -C.sub.6烷基、--(CH.sub.2).sub.2O(CH.sub.2).sub.2--或--(CH.sub.2).sub.2N(R.sub.6)(CH.sub.2).sub.2--（其中R.sub.6如上定义），--CONH(CH.sub.2).sub.m A（其中A如上定义，m为2到4的整数），--CH.dbd.CHCOR.sub.12（其中R.sub.12为羟基、C.sub.1 -C.sub.4烷氧基或--N(R.sub.13)(CH.sub.2).sub.nCO.sub.2R.sub.3（其中R.sub.13为氢、C.sub.1 -C.sub.6烷基或环烷基，R.sub.3如上定义，n为1到4的整数），--SR.sub.14（其中R.sub.14为C.sub.1 -C.sub.4烷基），--CN或（其中R.sub.3如上定义），或Y.sub.1、Y.sub.2和Y.sub.3中的两个一起形成（其中p为1或2）的结构式，以及其药用盐。

  公开号：

  US05098900A1
• 作为产物：
  描述：

  3-甲氧基苯甲酰胺 在 lithium aluminium tetrahydride 作用下， 生成 N-(3-methoxyphenylmethyl)carbamic acid ethyl ester
  参考文献：
  名称：

  Ring Enlargements. III. Ring Enlargement of Cyclohexanone with Ethyl N-Nitroso-N-Benzylcarbamates Carrying Methyl and Methoxyl Substituents on the Phenyl Nucleus

  摘要：

  DOI：

  10.1021/ja01606a035

文献信息

• Reactions of Cyclopropanone Acetals with Alkyl Azides:  Carbonyl Addition versus Ring-Opening Pathways
  作者：Scott Grecian、Pankaj Desai、Craig Mossman、Jennifer L. Poutsma、Jeffrey Aubé

  DOI：10.1021/jo0711034

  日期：2007.12.1

  bond cleavage of the corresponding cyclopropanone, giving oxyallyl cations that were captured by azides. Aryl-substituted cyclopropanone acetals, when subjected to these conditions, afforded [1,2,3]oxaborazoles exclusively, which were also the result of C2−C3 bond rupture, azide capture, and then loss of nitrogen. In the reactions of n-hexyl-substituted cyclopropanone acetals with alkyl azides, a mixture

  发现取代的环丙酮缩醛与烷基叠氮化物的路易斯酸介导的反应强烈依赖于酮组分的结构。当环丙酮缩醛用烷基叠氮化物处理时，分别获得了N-取代的 2-氮杂环丁酮和氨基甲酸乙酯产物，它们分别是由叠氮化物加成到羰基上，然后是扩环或重排产生的。BF 3 ·OEt 2存在下2,2-二甲基环丙酮缩醛与叠氮化物反应，获得的产物是 α-氨基-α'-重氮甲基酮，其产生于相应环丙酮的 C2-C3 键断裂，产生被叠氮化物捕获的氧烯丙基阳离子。芳基取代的环丙酮缩醛，在这些条件下，仅提供 [1,2,3] 恶唑啉，这也是 C2-C3 键断裂、叠氮化物捕获，然后失去氮的结果。在正己基取代的环丙酮缩醛与烷基叠氮化物的反应中，获得了 2-氮杂环丁酮和区域异构 [1,2,3] 恶硼唑的混合物。讨论了不同系统行为不同的原因。
• Application of Ag/TFPG-DMB COF in carbamates synthesis via CO2 fixation reaction and one-pot reductive N-formylation of nitroarenes under sunlight
  作者：Arpita Hazra Chowdhury、Ipsita Hazra Chowdhury、Surajit Biswas、Sk. Manirul Islam

  DOI：10.1016/j.mcat.2020.111050

  日期：2020.9

  We have designed mesoporous AgNPs decorated COF (Ag/TFPG-DMB COF) nanomaterial which has been formed by an easy ex-situ synthetic method. The synthesized material is characterized by FTIR, PXRD, UV-vis, N-2 adsorption-desorption studies, TEM, FESEM and XPS. The material showed the generation of identical mesopore at 3.9 nm. It is observed that the material can perform as both thermally and photochemically active catalyst for carbamate synthesis and one-pot reduction and N-formylation of nitroarenes respectively. The catalytic activity of the Ag/ TFPG-DMB COF nanomaterial is checked for green synthesis of carbamates from different amines and alcohols under 1 atmospheric pressure of CO2 with excellent yield (upto 95 %) as well as with high TOF value (182 h(-1)) and high selectivity. Additionally, the Ag/ TFPG-DMB COF nanomaterial is also applied as a potentially active photocatalyst for one-pot nitroarene reduction along with N-formylation reaction under sunlight irradiation in green reaction conditions with exceptionally high yield of formylated products upto 99 % as well as with high TOF value (762 h(-1)). The catalyst efficiently reduced and formylated para-nitrophenol, a potential water pollutant, which elaborates its scope as an efficient catalyst for water purification also. The catalyst recyclability is also checked for five reaction cycles for both the reactions and the Ag/TFPGDMB COF material showed outstanding recycling ability without any noticeable leaching of active metal or catalyst degradation.
• 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it
  申请人：NISSAN CHEMICAL INDUSTRIES LTD.

  公开号：EP0186817B1

  公开（公告）日：1989-08-02
• US5098900A
  申请人：——

  公开号：US5098900A

  公开（公告）日：1992-03-24
• 3(2H)pyridazinone, process for its preparation and anti-allergic agent
  申请人：Nissan Chemical Industries Ltd.

  公开号：US05098900A1

  公开（公告）日：1992-03-24

  A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is C.sub.2 -C.sub.5 alkyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.3 alkyl, chlorine or bromine; R.sub.3 is hydrogen or C.sub.1 -C.sub.4 alkyl; and each of Y.sub.1, Y.sub.2 and Y.sub.3 which may be the same or different, is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.2 -C.sub.8 alkenyl, halogen, --(CH.sub.2).sub.l A [wherein A is substituted amino of the formula --N(R.sub.4) (R.sub.5) (wherein each of R.sub.4 and R.sub.5 which may be the same or different, is C.sub.1 -C.sub.4 alkyl, or R.sub.4 and R.sub.5 together form C.sub.4 -C.sub.6 alkylene), morpholino, 4-R.sub.6 -piperazin-1-yl (wherein R.sub.6 is C.sub.1 -C.sub.3 alkyl) or --OR.sub.7 (wherein R.sub.7 is hydrogen or C.sub.1 -C.sub.3 alkyl), and l is an integer of 0 to 3], --OR.sub.8 [wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.5 alkenyl, benzyl or --(CH.sub.2).sub.q --R.sub.9 [wherein R.sub.9 is CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CONHR.sub.3 (wherein R.sub.3 is as defined above) or --CH.sub.2 OR.sub.7 (wherein R.sub.7 is as defined above), and q is an integer of 1 to 5]], --CO.sub.2 R.sub.3 (wherein R.sub.3 is as defined above), --CON(R.sub.10) (R.sub.11) [wherein each of R.sub.10 and R.sub.11 which may be the same or different, is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.5 alkenyl, or R.sub.10 and R.sub.11 together form C.sub.4 -C.sub.6 alkylene, --(CH.sub.2).sub.2 O(CH.sub.2).sub.2 -- or --(CH.sub.2).sub.2 N(R.sub.6)(CH.sub.2).sub.2 -- (wherein R.sub.6 is as defined above)], --CONH(CH.sub.2).sub.m A (wherein A is as defined above, and m is an integer of 2 to 4), --CH.dbd.CHCOR.sub.12 (wherein R.sub.12 is hydroxy, C.sub.1 -C.sub.4 alkoxy or --N(R.sub.13) (CH.sub.2).sub.n CO.sub.2 R.sub.3 (wherein R.sub.13 is hydrogen, C.sub.1 -C.sub.6 alkyl or cycloalkyl, R.sub.3 is as defined above, and n is an integer of 1 to 4)), --SR.sub.14 (wherein R.sub.14 is C.sub.1 -C.sub.4 alkyl), --CN or ##STR2## wherein R.sub.3 is as defined above), or two of Y.sub.1, Y.sub.2 and Y.sub.3 together form ##STR3## (wherein p is an integer of 1 or 2), and a pharmaceutically acceptable salt thereof.

  一种具有以下结构式的3(2H)吡啶并嗪酮化合物：其中R.sub.1是C.sub.2 -C.sub.5烷基；R.sub.2是氢、C.sub.1 -C.sub.3烷基、氯或溴；R.sub.3是氢或C.sub.1 -C.sub.4烷基；以及Y.sub.1、Y.sub.2和Y.sub.3中的每一个（可以相同也可以不同）是氢、C.sub.1 -C.sub.8烷基、C.sub.2 -C.sub.8烯基、卤素、--(CH.sub.2).sub.l A（其中A是具有以下结构式的取代氨基：--N(R.sub.4)(R.sub.5)（其中R.sub.4和R.sub.5可以相同也可以不同，为C.sub.1 -C.sub.4烷基，或R.sub.4和R.sub.5一起形成C.sub.4 -C.sub.6烷基）、吗啉基、4-R.sub.6-哌嗪-1-基（其中R.sub.6为C.sub.1 -C.sub.3烷基）或--OR.sub.7（其中R.sub.7为氢或C.sub.1 -C.sub.3烷基），l为0到3的整数，--OR.sub.8（其中R.sub.8为氢、C.sub.1 -C.sub.8烷基、C.sub.3 -C.sub.5烯基、苄基或--(CH.sub.2).sub.q --R.sub.9（其中R.sub.9为CO.sub.2R.sub.3（其中R.sub.3如上定义）、--CONHR.sub.3（其中R.sub.3如上定义）或--CH.sub.2OR.sub.7（其中R.sub.7如上定义），q为1到5的整数）]，--CO.sub.2R.sub.3（其中R.sub.3如上定义），--CON(R.sub.10)(R.sub.11)（其中R.sub.10和R.sub.11可以相同也可以不同，为氢、C.sub.1 -C.sub.4烷基或C.sub.3 -C.sub.5烯基，或R.sub.10和R.sub.11一起形成C.sub.4 -C.sub.6烷基、--(CH.sub.2).sub.2O(CH.sub.2).sub.2--或--(CH.sub.2).sub.2N(R.sub.6)(CH.sub.2).sub.2--（其中R.sub.6如上定义），--CONH(CH.sub.2).sub.m A（其中A如上定义，m为2到4的整数），--CH.dbd.CHCOR.sub.12（其中R.sub.12为羟基、C.sub.1 -C.sub.4烷氧基或--N(R.sub.13)(CH.sub.2).sub.nCO.sub.2R.sub.3（其中R.sub.13为氢、C.sub.1 -C.sub.6烷基或环烷基，R.sub.3如上定义，n为1到4的整数），--SR.sub.14（其中R.sub.14为C.sub.1 -C.sub.4烷基），--CN或（其中R.sub.3如上定义），或Y.sub.1、Y.sub.2和Y.sub.3中的两个一起形成（其中p为1或2）的结构式，以及其药用盐。